Kukje Pharma Co., Ltd. (002720.KS)
KRW 4970.0
(-2.17%)
KRW 4970.0
(-2.17%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 170.61 Billion KRW | 24.91% |
| 2022 | 136.59 Billion KRW | -2.28% |
| 2021 | 139.78 Billion KRW | -4.01% |
| 2020 | 145.62 Billion KRW | 8.2% |
| 2019 | 134.59 Billion KRW | 6.62% |
| 2018 | 126.23 Billion KRW | -4.11% |
| 2017 | 131.64 Billion KRW | 1.69% |
| 2016 | 129.45 Billion KRW | -5.26% |
| 2015 | 136.64 Billion KRW | 16.28% |
| 2014 | 117.5 Billion KRW | 0.07% |
| 2013 | 117.43 Billion KRW | 2.18% |
| 2012 | 114.92 Billion KRW | -18.85% |
| 2011 | 141.61 Billion KRW | -1.49% |
| 2010 | 143.76 Billion KRW | 7.53% |
| 2009 | 133.69 Billion KRW | 6.95% |
| 2008 | 125 Billion KRW | 28.93% |
| 2007 | 96.95 Billion KRW | 2.36% |
| 2006 | 94.72 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 159.45 Billion KRW | -2.96% |
| 2024 Q1 | 164.31 Billion KRW | -3.69% |
| 2023 Q3 | 138.53 Billion KRW | -2.7% |
| 2023 Q4 | 170.61 Billion KRW | 23.16% |
| 2023 Q1 | 139.38 Billion KRW | 2.05% |
| 2023 Q2 | 142.37 Billion KRW | 2.15% |
| 2023 FY | 170.61 Billion KRW | 24.91% |
| 2022 Q1 | 145.91 Billion KRW | 4.39% |
| 2022 FY | 136.59 Billion KRW | -2.28% |
| 2022 Q4 | 136.59 Billion KRW | -4.28% |
| 2022 Q3 | 142.69 Billion KRW | -1.57% |
| 2022 Q2 | 144.98 Billion KRW | -0.64% |
| 2021 Q2 | 145.43 Billion KRW | -0.52% |
| 2021 Q1 | 146.18 Billion KRW | 0.39% |
| 2021 FY | 139.78 Billion KRW | -4.01% |
| 2021 Q4 | 139.78 Billion KRW | -3.7% |
| 2021 Q3 | 145.16 Billion KRW | -0.19% |
| 2020 Q1 | 140.49 Billion KRW | 4.38% |
| 2020 Q3 | 151.18 Billion KRW | -1.43% |
| 2020 Q4 | 145.62 Billion KRW | -3.68% |
| 2020 FY | 145.62 Billion KRW | 8.2% |
| 2020 Q2 | 153.38 Billion KRW | 9.18% |
| 2019 Q4 | 134.59 Billion KRW | 0.82% |
| 2019 FY | 134.59 Billion KRW | 6.62% |
| 2019 Q3 | 133.5 Billion KRW | -4.45% |
| 2019 Q2 | 139.71 Billion KRW | 1.89% |
| 2019 Q1 | 137.12 Billion KRW | 8.63% |
| 2018 Q4 | 126.23 Billion KRW | -0.55% |
| 2018 FY | 126.23 Billion KRW | -4.11% |
| 2018 Q1 | 129.83 Billion KRW | -1.37% |
| 2018 Q2 | 128.09 Billion KRW | -1.35% |
| 2018 Q3 | 126.93 Billion KRW | -0.9% |
| 2017 Q1 | 131.34 Billion KRW | 1.46% |
| 2017 FY | 131.64 Billion KRW | 1.69% |
| 2017 Q4 | 131.64 Billion KRW | -3.17% |
| 2017 Q3 | 135.95 Billion KRW | 4.51% |
| 2017 Q2 | 130.08 Billion KRW | -0.96% |
| 2016 Q3 | 132.03 Billion KRW | -5.28% |
| 2016 Q2 | 139.39 Billion KRW | 1.19% |
| 2016 Q1 | 137.75 Billion KRW | 0.81% |
| 2016 FY | 129.45 Billion KRW | -5.26% |
| 2016 Q4 | 129.45 Billion KRW | -1.95% |
| 2015 Q3 | 145.54 Billion KRW | -0.24% |
| 2015 Q2 | 145.9 Billion KRW | 21.92% |
| 2015 Q1 | 119.66 Billion KRW | 1.84% |
| 2015 FY | 136.64 Billion KRW | 16.28% |
| 2015 Q4 | 136.64 Billion KRW | -6.12% |
| 2014 Q3 | 118.82 Billion KRW | -0.71% |
| 2014 Q1 | 117.59 Billion KRW | 0.14% |
| 2014 Q4 | 117.5 Billion KRW | -1.11% |
| 2014 FY | 117.5 Billion KRW | 0.07% |
| 2014 Q2 | 119.66 Billion KRW | 1.76% |
| 2013 FY | 117.43 Billion KRW | 2.18% |
| 2013 Q2 | 120.05 Billion KRW | 1.1% |
| 2013 Q3 | 115.98 Billion KRW | -3.39% |
| 2013 Q4 | 117.43 Billion KRW | 1.25% |
| 2013 Q1 | 118.74 Billion KRW | 3.33% |
| 2012 Q1 | 138.97 Billion KRW | 0.0% |
| 2012 Q4 | 114.92 Billion KRW | 0.0% |
| 2012 FY | 114.92 Billion KRW | -18.85% |
| 2011 FY | 141.61 Billion KRW | -1.49% |
| 2011 Q1 | 143.76 Billion KRW | -0.82% |
| 2011 Q2 | 137.94 Billion KRW | -4.04% |
| 2011 Q3 | 135.8 Billion KRW | -1.55% |
| 2010 Q4 | 144.94 Billion KRW | -1.12% |
| 2010 FY | 143.76 Billion KRW | 7.53% |
| 2010 Q2 | 143.9 Billion KRW | 7.64% |
| 2010 Q3 | 146.58 Billion KRW | 1.87% |
| 2010 Q1 | 133.69 Billion KRW | -4.74% |
| 2009 FY | 133.69 Billion KRW | 6.95% |
| 2009 Q4 | 140.34 Billion KRW | 0.19% |
| 2009 Q3 | 140.06 Billion KRW | -2.1% |
| 2009 Q2 | 143.07 Billion KRW | 14.46% |
| 2009 Q1 | 125 Billion KRW | -2.07% |
| 2008 Q1 | 96.95 Billion KRW | -3.98% |
| 2008 Q2 | 112.05 Billion KRW | 15.57% |
| 2008 Q4 | 127.65 Billion KRW | 7.59% |
| 2008 Q3 | 118.64 Billion KRW | 5.88% |
| 2008 FY | 125 Billion KRW | 28.93% |
| 2007 Q2 | 100.27 Billion KRW | 0.0% |
| 2007 Q4 | 100.97 Billion KRW | 1.81% |
| 2007 FY | 96.95 Billion KRW | 2.36% |
| 2007 Q3 | 99.18 Billion KRW | -1.09% |
| 2006 FY | 94.72 Billion KRW | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 198.21 Billion KRW | 13.921% |
| Dong-A Socio Holdings Co., Ltd. | 1957.1 Billion KRW | 91.282% |
| Ildong Holdings Co., Ltd. | 876.99 Billion KRW | 80.545% |
| HANDOK Inc. | 790.33 Billion KRW | 78.412% |
| Yuhan Corporation | 2814.07 Billion KRW | 93.937% |
| Dong-A ST Co., Ltd. | 1315.21 Billion KRW | 87.027% |
| SAMSUNG PHARM. Co., LTD. | 93.47 Billion KRW | -82.522% |
| Hanmi Pharm. Co., Ltd. | 1952.03 Billion KRW | 91.259% |
| Hanall Biopharma Co.,Ltd | 239.74 Billion KRW | 28.833% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | 63.613% |
| Dong Sung Bio Pharm.Co.,Ltd. | 114.97 Billion KRW | -48.4% |
| MYUNGMOON Pharm co.,Ltd | 236.54 Billion KRW | 27.871% |
| Hana Pharm Co., Ltd. | 348.38 Billion KRW | 51.026% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | 13.921% |
| Ilsung Pharmaceuticals Co., Ltd. | 419.18 Billion KRW | 59.298% |
| REYON Pharmaceutical Co., Ltd. | 499.77 Billion KRW | 65.861% |
| Aprogen pharmaceuticals,Inc. | 589.39 Billion KRW | 71.052% |
| JW Holdings Corporation | 1176.26 Billion KRW | 85.495% |
| Ildong Pharmaceutical Co., Ltd. | 611.26 Billion KRW | 72.087% |
| Chong Kun Dang Pharmaceutical Corp. | 1402.42 Billion KRW | 87.834% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 73.549% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | 51.263% |
| Hyundai Pharmaceutical Co., Ltd. | 154.04 Billion KRW | -10.763% |
| Samil Pharmaceutical Co.,Ltd | 370.68 Billion KRW | 53.971% |
| Jeil Pharmaceutical Co.,Ltd | 487.32 Billion KRW | 64.989% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | 13.921% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1078.06 Billion KRW | 84.174% |
| Daewoong pharmaceutical Co.,Ltd | 1770.31 Billion KRW | 90.362% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 73.549% |
| Yuhan Corporation | 2814.07 Billion KRW | 93.937% |
| Jeil Pharma Holdings Inc | 879.99 Billion KRW | 80.611% |
| Yungjin Pharm. Co., Ltd. | 226.6 Billion KRW | 24.705% |
| Suheung Co., Ltd. | 993.73 Billion KRW | 82.83% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 73.549% |
| Samjin Pharmaceuticals Co., Ltd. | 419.9 Billion KRW | 59.367% |
| Korea United Pharm Inc. | 468.86 Billion KRW | 63.61% |
| CKD Bio Corp. | 293.78 Billion KRW | 41.924% |
| Daewon Pharmaceutical Co., Ltd. | 507.99 Billion KRW | 66.413% |
| Dongwha Pharm.Co.,Ltd | 564.97 Billion KRW | 69.8% |
| Whan In Pharm Co.,Ltd. | 401.22 Billion KRW | 57.475% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | 51.263% |
| Chong Kun Dang Holdings Corp. | 1456 Billion KRW | 88.282% |
| Boryung Corporation | 922.36 Billion KRW | 81.502% |
| Bukwang Pharmaceutical Co., Ltd. | 442.46 Billion KRW | 61.439% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | 63.613% |
| JW Lifescience Corporation | 255.83 Billion KRW | 33.309% |